Treatment of HBeAg-Positive Hepatitis B with Peginterferon and Lamivudine
To the Editor: Lau et al. (June 30 issue) 1 studied pegylated interferon for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Overall, HBeAg seroconversion was highest among patients treated with pegylated interferon monotherapy, despite the more potent hepatitis B virus...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2005-10, Vol.353 (15), p.1630-1631 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1631 |
|---|---|
| container_issue | 15 |
| container_start_page | 1630 |
| container_title | The New England journal of medicine |
| container_volume | 353 |
| creator | Song, Kenneth Rajvanshi, Pankaj |
| description | To the Editor:
Lau et al. (June 30 issue)
1
studied pegylated interferon for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Overall, HBeAg seroconversion was highest among patients treated with pegylated interferon monotherapy, despite the more potent hepatitis B virus (HBV) DNA suppression with lamivudine at 48 weeks. Although viral suppression and HBeAg seroconversion are well correlated,
2
the degree of viral suppression needed for seroconversion to occur is not well defined. With regard to this study, it would be of interest to know what the degree of HBV DNA suppression was among patients in whom HBeAg or . . . |
| doi_str_mv | 10.1056/NEJMc052065 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68694384</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68685216</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-b91935ae9a8b47ec188d45f15d885a0fcef86929f163ffb70bbaea8d4a4d442a3</originalsourceid><addsrcrecordid>eNqN0D1PwzAQBmALgWgpTOzIEhILCvgzcUZaFVpUoEOZIyc5F1dNUmyniH9PUCvBwICX8_Dce9KL0DklN5TI-PZ5_PhUEMlILA9Qn0rOIyFIfIj6hDAViSTlPXTi_Yp0j4r0GPVozBhNUtZH04UDHSqoA24MngzhbhnNG2-D3QKewEaH7uvxEH_Y8IbnsLR1AGfANTXWdYlnurLbtrQ1nKIjo9cezvZzgF7vx4vRJJq9PExHd7Oo4IKHKE9pyqWGVKtcJFBQpUohDZWlUlITU4BRccpSQ2NuTJ6QPNegO6NFKQTTfICudrkb17y34ENWWV_Aeq1raFqfxd264Er8ByrJujMDdL2DhWu8d2CyjbOVdp8ZJdl3xdmvijt9sY9t8wrKH7vvtAOXO1BVPqthVf0Z8wWry4Dg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68685216</pqid></control><display><type>article</type><title>Treatment of HBeAg-Positive Hepatitis B with Peginterferon and Lamivudine</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>New England Journal of Medicine Current</source><creator>Song, Kenneth ; Rajvanshi, Pankaj</creator><creatorcontrib>Song, Kenneth ; Rajvanshi, Pankaj</creatorcontrib><description>To the Editor:
Lau et al. (June 30 issue)
1
studied pegylated interferon for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Overall, HBeAg seroconversion was highest among patients treated with pegylated interferon monotherapy, despite the more potent hepatitis B virus (HBV) DNA suppression with lamivudine at 48 weeks. Although viral suppression and HBeAg seroconversion are well correlated,
2
the degree of viral suppression needed for seroconversion to occur is not well defined. With regard to this study, it would be of interest to know what the degree of HBV DNA suppression was among patients in whom HBeAg or . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc052065</identifier><identifier>PMID: 16221792</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Antiviral Agents - therapeutic use ; DNA, Viral - blood ; Drug Therapy, Combination ; Hepatitis B e Antigens - blood ; Hepatitis B virus - drug effects ; Hepatitis B virus - genetics ; Hepatitis B, Chronic - drug therapy ; Humans ; Interferon-alpha - therapeutic use ; Lamivudine - therapeutic use ; Polyethylene Glycols - therapeutic use ; Recombinant Proteins</subject><ispartof>The New England journal of medicine, 2005-10, Vol.353 (15), p.1630-1631</ispartof><rights>Copyright © 2005 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c343t-b91935ae9a8b47ec188d45f15d885a0fcef86929f163ffb70bbaea8d4a4d442a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc052065$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMc052065$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16221792$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Song, Kenneth</creatorcontrib><creatorcontrib>Rajvanshi, Pankaj</creatorcontrib><title>Treatment of HBeAg-Positive Hepatitis B with Peginterferon and Lamivudine</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Lau et al. (June 30 issue)
1
studied pegylated interferon for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Overall, HBeAg seroconversion was highest among patients treated with pegylated interferon monotherapy, despite the more potent hepatitis B virus (HBV) DNA suppression with lamivudine at 48 weeks. Although viral suppression and HBeAg seroconversion are well correlated,
2
the degree of viral suppression needed for seroconversion to occur is not well defined. With regard to this study, it would be of interest to know what the degree of HBV DNA suppression was among patients in whom HBeAg or . . .</description><subject>Antiviral Agents - therapeutic use</subject><subject>DNA, Viral - blood</subject><subject>Drug Therapy, Combination</subject><subject>Hepatitis B e Antigens - blood</subject><subject>Hepatitis B virus - drug effects</subject><subject>Hepatitis B virus - genetics</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Humans</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Lamivudine - therapeutic use</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Recombinant Proteins</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0D1PwzAQBmALgWgpTOzIEhILCvgzcUZaFVpUoEOZIyc5F1dNUmyniH9PUCvBwICX8_Dce9KL0DklN5TI-PZ5_PhUEMlILA9Qn0rOIyFIfIj6hDAViSTlPXTi_Yp0j4r0GPVozBhNUtZH04UDHSqoA24MngzhbhnNG2-D3QKewEaH7uvxEH_Y8IbnsLR1AGfANTXWdYlnurLbtrQ1nKIjo9cezvZzgF7vx4vRJJq9PExHd7Oo4IKHKE9pyqWGVKtcJFBQpUohDZWlUlITU4BRccpSQ2NuTJ6QPNegO6NFKQTTfICudrkb17y34ENWWV_Aeq1raFqfxd264Er8ByrJujMDdL2DhWu8d2CyjbOVdp8ZJdl3xdmvijt9sY9t8wrKH7vvtAOXO1BVPqthVf0Z8wWry4Dg</recordid><startdate>20051013</startdate><enddate>20051013</enddate><creator>Song, Kenneth</creator><creator>Rajvanshi, Pankaj</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20051013</creationdate><title>Treatment of HBeAg-Positive Hepatitis B with Peginterferon and Lamivudine</title><author>Song, Kenneth ; Rajvanshi, Pankaj</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-b91935ae9a8b47ec188d45f15d885a0fcef86929f163ffb70bbaea8d4a4d442a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>DNA, Viral - blood</topic><topic>Drug Therapy, Combination</topic><topic>Hepatitis B e Antigens - blood</topic><topic>Hepatitis B virus - drug effects</topic><topic>Hepatitis B virus - genetics</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Humans</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Lamivudine - therapeutic use</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Recombinant Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Song, Kenneth</creatorcontrib><creatorcontrib>Rajvanshi, Pankaj</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Song, Kenneth</au><au>Rajvanshi, Pankaj</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of HBeAg-Positive Hepatitis B with Peginterferon and Lamivudine</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2005-10-13</date><risdate>2005</risdate><volume>353</volume><issue>15</issue><spage>1630</spage><epage>1631</epage><pages>1630-1631</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
Lau et al. (June 30 issue)
1
studied pegylated interferon for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Overall, HBeAg seroconversion was highest among patients treated with pegylated interferon monotherapy, despite the more potent hepatitis B virus (HBV) DNA suppression with lamivudine at 48 weeks. Although viral suppression and HBeAg seroconversion are well correlated,
2
the degree of viral suppression needed for seroconversion to occur is not well defined. With regard to this study, it would be of interest to know what the degree of HBV DNA suppression was among patients in whom HBeAg or . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>16221792</pmid><doi>10.1056/NEJMc052065</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2005-10, Vol.353 (15), p.1630-1631 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68694384 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; New England Journal of Medicine Current |
| subjects | Antiviral Agents - therapeutic use DNA, Viral - blood Drug Therapy, Combination Hepatitis B e Antigens - blood Hepatitis B virus - drug effects Hepatitis B virus - genetics Hepatitis B, Chronic - drug therapy Humans Interferon-alpha - therapeutic use Lamivudine - therapeutic use Polyethylene Glycols - therapeutic use Recombinant Proteins |
| title | Treatment of HBeAg-Positive Hepatitis B with Peginterferon and Lamivudine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T13%3A13%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20HBeAg-Positive%20Hepatitis%20B%20with%20Peginterferon%20and%20Lamivudine&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Song,%20Kenneth&rft.date=2005-10-13&rft.volume=353&rft.issue=15&rft.spage=1630&rft.epage=1631&rft.pages=1630-1631&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc052065&rft_dat=%3Cproquest_cross%3E68685216%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68685216&rft_id=info:pmid/16221792&rfr_iscdi=true |